U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H25N5O3S
Molecular Weight 463.552
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BERZOSERTIB

SMILES

CNCC1=CC=C(C=C1)C2=NOC(=C2)C3=NC(=CN=C3N)C4=CC=C(C=C4)S(=O)(=O)C(C)C

InChI

InChIKey=JZCWLJDSIRUGIN-UHFFFAOYSA-N
InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)

HIDE SMILES / InChI
Molecular Formula C24H25N5O3S
Molecular Weight 463.552
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23222511

VX-970 (VE-822) is an ATR kinase inhibitor. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. Vertex Pharmaceuticals is developing VX 970 for the treatment of advanced solid tumours. Phase I/II development is underway in the US for small-cell lung cancer and in the UK for solid tumours. Phase II development of VX 970 as a combination therapy in urogenital cancer, ovarian, primary peritoneal and fallopian tube cancer indications is underway in the US.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 0.2 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4410 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32568634
480 mg/m² single, intravenous
dose: 480 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VX-970 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1520 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32568634
240 mg/m² 1 times / week single, intravenous
dose: 240 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VX-970 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14900 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32568634
480 mg/m² single, intravenous
dose: 480 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VX-970 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8270 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32568634
240 mg/m² 1 times / week single, intravenous
dose: 240 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VX-970 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
21.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32568634
480 mg/m² single, intravenous
dose: 480 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VX-970 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17.9 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32568634
240 mg/m² 1 times / week single, intravenous
dose: 240 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VX-970 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
240 mg/m2 2 times / week multiple, intravenous
RP2D
Dose: 240 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 240 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/32568634
Page: p.3197
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/32568634
Page: p.3197
Sources:
https://pubmed.ncbi.nlm.nih.gov/32568634
Page: p.3197
480 mg/m2 1 times / week multiple, intravenous
Studied dose
Dose: 480 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 480 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/32568634
Page: p.3197
unhealthy, ADULT
n = 7
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/32568634
Page: p.3197
Sources:
https://pubmed.ncbi.nlm.nih.gov/32568634
Page: p.3197
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1461
UGTs
13
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1819
 weak [IC50 >30 uM]
CYP3A4
1925
 weak [IC50 >30 uM]
CYP2D6
1891
 weak
P-gp
1650
 yes [IC50 1.2995 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
UGTs
13
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
PubMed

PubMed

TitleDatePubMed
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
2011 Apr 14
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
2012 Dec 6
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
2014 Dec 1
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.
2014 Jul 30
Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.
2015
Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.
2016 Nov
Patents

Patents

20100222318
2
2010071837A1
2
WO2016112374A2
2

Sample Use Guides

In Vivo Use Guide
Intravenous VX-970 (VE-822) is in clinical trials for the treatment of cancer, however dosage is not known. VX-970 (VE-822) (30-60 mg/kg) was administered by oral gavage in mouse cancer xenograft models.
Route of Administration: Other
In Vitro Use Guide
80 nM VX-970 (VE-822) attenuates ATR signaling in normal cells without enhancing radiation and gemcitabine killing in normal cells.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:52:06 GMT 2023
Edited
by admin
on Sat Dec 16 10:52:06 GMT 2023
Record UNII
L423PRV3V3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BERZOSERTIB
USAN   INN  
Official Name English
3-(3-{4-[(Methylamino)methyl]phenyl}-1,2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine
Systematic Name English
Berzosertib [WHO-DD]
Common Name English
M6620
Code English
2-PYRAZINAMINE, 3-(3-(4-((METHYLAMINO)METHYL)PHENYL)-5-ISOXAZOLYL)-5-(4-((1-METHYLETHYL)SULFONYL)PHENYL)-
Systematic Name English
VX970
Code English
BERZOSERTIB [USAN]
Common Name English
M-6620
Code English
berzosertib [INN]
Common Name English
VE-822
Code English
VX-970
Code English
Code System Code Type Description
ChEMBL
CHEMBL3545202
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
DRUG BANK
DB11794
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
NCI_THESAURUS
C116355
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
EPA CompTox
DTXSID601025940
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
CAS
1232416-25-9
Created by admin on Sat Dec 16 10:52:06 GMT 2023 , Edited by admin on Sat Dec 16 10:52:06 GMT 2023
PRIMARY
SMS_ID
100000175098
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
WIKIPEDIA
Berzosertib
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
FDA UNII
L423PRV3V3
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
INN
10538
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
INCB IDS CODE
10538
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
USAN
DE-73
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
PUBCHEM
59472121
Created by admin on Sat Dec 16 10:52:07 GMT 2023 , Edited by admin on Sat Dec 16 10:52:07 GMT 2023
PRIMARY
Related Record Type Details
SERINE-PROTEIN KINASE ATM
TARGET -> INHIBITOR
Structure of BERZOSERTIB HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of BERZOSERTIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966